Tetsuro Takayama

Takanori Kanai2
Hidetsugu Saito1
2Takanori Kanai
1Hidetsugu Saito
Learn More
  • Tetsuro Takayama, Hirotoshi Ebinuma, Shinichiro Tada, Yoshiyuki Yamagishi, Kanji Wakabayashi, Keisuke Ojiro +3 others
  • 2011
Treatment with pegylated interferon alpha-2b (PEGIFN) plus ribavirin (RBV) is standard therapy for patients with chronic hepatitis C. Although the effectiveness, patients with high titres of group Ib hepatitis C virus (HCV) respond poorly compared to other genotypes. At present, we cannot predict the effect in an individual. Previous studies have used(More)
OBJECTIVE This study aimed to predict the 6-year incidence of metabolic syndrome (MetS) using an artificial neural network (ANN) system and multiple logistic regression (MLR) analysis based on clinical factors, including the insulin resistance index calculated by homeostasis model assessment (HOMA-IR). DESIGN Subjects were recruited from participants in(More)
  • Tetsuro Takayama, Susumu Okamoto, Tadakazu Hisamatsu, Makoto Naganuma, Katsuyoshi Matsuoka, Shinta Mizuno +4 others
  • 2015
Cytoapheresis (CAP) therapy is widely used in ulcerative colitis (UC) patients with moderate to severe activity in Japan. The aim of this study is to predict the need of operation after CAP therapy of UC patients on an individual level using an artificial neural network system (ANN). Ninety UC patients with moderate to severe activity were treated with CAP.(More)
  • 1